SORBA.ai and Labtopia Partner on Digital Twins

- SORBA.ai offers a no-code industrial AI platform designed to enable engineers and subject matter experts, without a data science background, to build predictive models, optimize production, and deploy autonomous control systems. The platform includes features for predictive maintenance, digital twin simulation, and advanced process control. - Labtopia, a woman-owned small business founded in 2006, specializes in quality assurance and control for regulated industries, providing services like LIMS implementation, quality system development, and staffing. Their expertise spans various quality standards, including ISO and GMP, and they have assisted over 200 organizations with quality management system implementation. - The partnership's goal is to shift laboratories from traditional data reporting roles to becoming active, real-time contributors to operational performance by combining Labtopia's consulting and LIMS expertise with SORBA.ai's AI platform. - A digital twin in biomanufacturing is a virtual replica of a physical process or system, such as a bioreactor, which is continuously updated with real-time data from sensors. This allows for the simulation of different scenarios to optimize performance and predict outcomes without impacting the actual production environment. - This collaboration addresses common challenges in LIMS implementation, such as the need for extensive customization, integrating with existing instruments, and migrating historical data, by leveraging AI to enhance data utilization and system interoperability. - The application of digital twins aligns with the Pharma 4.0 initiative, which promotes the use of digital technologies to create more adaptive and efficient manufacturing processes in GMP environments. This enables real-time monitoring and predictive maintenance, helping to minimize downtime and avoid regulatory deviations. - In the context of cell and gene therapy, the lack of manufacturing standardization is a significant hurdle to meeting the growing demand, with current capacity only meeting an estimated 20% of total patient needs. Digitalization and standardization are seen as critical for improving the efficiency and reliability of the vein-to-vein supply chain. - Data integrity and governance are crucial in cell and gene therapy, where a patient's cells are both the raw material and the final product. Digital systems must ensure that data is complete, consistent, accurate, and trustworthy throughout the entire data lifecycle to comply with cGMP regulations.